Allergan Inc (AGN)

AGN (NYSE:Drugs)
$172.13
pos +1.23
+0.72%
Today's Range: 171.09 - 172.64 | AGN Avg Daily Volume: 2,999,000
Last Update: 07/30/14 - 1:26 PM EDT
Volume: 752,695
YTD Performance: 53.85%
Open: $171.53
Previous Close: $170.90
52 Week Range: $86.95 - $174.49
Oustanding Shares: 297,556,619
Market Cap: 50,504,702,627
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 8
Moderate Buy 0 0 0 0
Hold 6 7 7 5
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.23 2.29 2.29 2.00
Latest Dividend: 0.05
Latest Dividend Yield: 0.12%
Dividend Ex-Date: 08/13/14
Price Earnings Ratio: 36.13
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
36.13 40.30 28.94
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.18% 89.34% 110.18%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.50 0.28 0.09
Net Income -10.30 258.69 5.26
EPS -9.80 0.00 0.00
Earnings for AGN:
EBITDA 2.07B
Revenue 6.30B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.47 $1.64 $5.79 $8.26
Number of Analysts 10 10 13 12
High Estimate $1.55 $1.70 $5.82 $8.37
Low Estimate $1.44 $1.53 $5.75 $7.74
Prior Year $1.23 $1.35 $4.77 $5.79
Growth Rate (Year over Year) 19.19% 21.70% 21.38% 42.63%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishAllergan upgraded at UBS

Jul 22, 2014 | 8:21 AM EDT

AGN was upgraded from Neutral to Buy, UBS said. $200 price target. The company plans to see more sales growth, while they consider a deal with Valeant.

bullishAllergan estimates, target raised at Leerink

Jul 22, 2014 | 7:21 AM EDT

Shares of AGN now seen reaching $184, according to Leerink Swann. Estimates also increased, as the company is aggressively cutting costs. Market Perform rating. 

By

Jim Cramer

 | Jul 21, 2014 | 3:53 PM EDT

The consensus of positives is just too cute.

By

Jim Cramer

 | Jul 17, 2014 | 1:10 PM EDT

There are amazing cross currents that make fundamental security analysis hard.

By

Jim Cramer

 | Jul 10, 2014 | 5:35 AM EDT

Cheap money and greed from the Allergan bidder's side are strong incentives.

By

Jim Cramer

 | Jul 9, 2014 | 6:44 AM EDT

Here are several themes that are still working -- and now you can get in at a bargain.

By

Doug Kass

 | Jun 10, 2014 | 8:20 AM EDT
No thanks!

bearishAllergan downgraded at Credit Suisse

Jun 3, 2014 | 8:02 AM EDT

AGN was downgraded from Outperform to Neutral, Credit Suisse said. $190 price target. Risk/reward is balanced, following the latest bid from Valeant. 

By

Jim Cramer

 | Jun 2, 2014 | 2:00 PM EDT

Let's look at how wrong this whole concept is.

By

Jim Cramer

 | May 16, 2014 | 7:30 AM EDT

You should be watching how DexCom is trading.

Jim C., the EUR has been in a secular downtrend since August 2008. The ECB has been tryin...
YELP is trading $73.56, up 5.9% small with IV30™ up 6.4%. This is stock ans vol note...
Cramer:  
FXE
Did Obama make some sort of deal with the Europeans to let the dollar rise in order to buy...
The market has given its Q2 GDP driven gains earlier in day and is now down with the excep...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.